Cost per median overall survival month for abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

被引：0
|
作者：
Pilon, Dominic
Lefebvre, Patrick
Queener, Marykay
Ellis, Lorie
机构：
[1] Grp Anal Ltee, Montreal, PQ, Canada
[2] Janssen Sci Affairs LLC, Horsham, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e16080
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16080
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Enzalutamide (ENZA) in combination with abiraterone acetate (AA) in bone metastatic castration resistant prostate cancer (mCRPC)
    Efstathiou, Eleni
    Titus, Mark Anton
    Wen, Sijin
    SanMiguel, Aileen
    Hoang, Anh
    De Haas-Amatsaleh, Angela
    Perabo, Frank
    De Phung
    Troncoso, Patricia
    Ouatas, Taoufik
    Logothetis, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [22] Comparison of abiraterone and enzalutamide in patients with metastatic castration-resistant prostate cancer in Taiwan
    Ni, Hsueh Fen
    Li, Jian-Ri
    INTERNATIONAL JOURNAL OF UROLOGY, 2022, 29 : 60 - 60
  • [23] Real-world (RW) overall survival (OS) with enzalutamide (ENZ) and abiraterone acetate (ABI) in patients (pts) with chemotherapy (cx)-naive metastatic castration-resistant prostate cancer (mCRPC)
    George, D. J.
    Ramaswamy, K.
    Yang, H.
    Liu, Q.
    Zhang, A.
    Greatsinger, A.
    Ivanova, J.
    Thompson, B.
    Emir, B.
    Hong, A.
    Freedland, S. J.
    ANNALS OF ONCOLOGY, 2023, 34 : S989 - S990
  • [24] Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide
    Noonan, K. L.
    North, S.
    Bitting, R. L.
    Armstrong, A. J.
    Ellard, S. L.
    Chi, K. N.
    ANNALS OF ONCOLOGY, 2013, 24 (07) : 1802 - 1807
  • [25] ABIRATERONE ACETATE VERSUS ENZALUTAMIDE FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER POST CHEMOTHERAPY: COST EFFECTIVENESS ANALYSIS
    He, J.
    Li, T.
    Saadi, R.
    VALUE IN HEALTH, 2013, 16 (07) : A411 - A411
  • [26] An indirect treatment comparison (ITC) and cost-effectiveness analysis of abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC) post-chemotherapy.
    Li, Tracy
    Thompson, Melissa
    Todd, Mary Beth
    Yu, Margaret K.
    Kheoh, Thian San
    He, Jianming
    Saadi, Ryan
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [27] Treatment duration and utilization patterns in metastatic castration-resistant prostate cancer patients receiving enzalutamide or abiraterone acetate.
    Kassabian, Vahan
    Flanders, Scott
    Wilson, Samuel
    Brown, Bruce A.
    Song, Yan
    Yang, Hongbo
    Lechpammer, Stanislav
    Schultz, Neil M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [28] Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer
    George, Daniel J.
    Ramaswamy, Krishnan
    Yang, Hongbo
    Liu, Qing
    Zhang, Adina
    Greatsinger, Alexandra
    Ivanova, Jasmina
    Thompson, Betty
    Emir, Birol
    Hong, Agnes
    Freedland, Stephen J.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2024, 27 (04) : 756 - 764
  • [29] Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer
    Tseng, Chi-Shin
    Yang, Jui-Han
    Huang, Shi-Wei
    Wang, Yu-Jen
    Chen, Chung-Hsin
    Pu, Yeong-Shiau
    Cheng, Jason Chia-Hsien
    Huang, Chao-Yuan
    BMC CANCER, 2023, 23 (01)
  • [30] Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer
    Chi-Shin Tseng
    Jui-Han Yang
    Shi-Wei Huang
    Yu-Jen Wang
    Chung-Hsin Chen
    Yeong-Shiau Pu
    Jason Chia-Hsien Cheng
    Chao-Yuan Huang
    BMC Cancer, 23
12345